Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Yu X, Orr CM, Chan HTC, James S, Penfold CA, Kim J, Inzhelevskaya T, Mockridge CI, Cox KL, Essex JW, Tews I, Glennie MJ, Cragg MS. Yu X, et al. Among authors: glennie mj. Nature. 2023 Feb;614(7948):539-547. doi: 10.1038/s41586-022-05673-2. Epub 2023 Feb 1. Nature. 2023. PMID: 36725933
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.
Orr CM, Fisher H, Yu X, Chan CH, Gao Y, Duriez PJ, Booth SG, Elliott I, Inzhelevskaya T, Mockridge I, Penfold CA, Wagner A, Glennie MJ, White AL, Essex JW, Pearson AR, Cragg MS, Tews I. Orr CM, et al. Among authors: glennie mj. Sci Immunol. 2022 Jul 15;7(73):eabm3723. doi: 10.1126/sciimmunol.abm3723. Epub 2022 Jul 8. Sci Immunol. 2022. PMID: 35857577
HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy.
Hussain K, Liu R, Smith RCG, Müller KTJ, Ghorbani M, Macari S, Cleary KLS, Oldham RJ, Foxall RB, James S, Booth SG, Murray T, Dahal LN, Hargreaves CE, Kemp RS, Longley J, Douglas J, Markham H, Chee SJ, Stopforth RJ, Roghanian A, Carter MJ, Ottensmeier CH, Frendéus B, Cutress RI, French RR, Glennie MJ, Strefford JC, Thirdborough SM, Beers SA, Cragg MS. Hussain K, et al. Among authors: glennie mj. J Exp Clin Cancer Res. 2022 Apr 7;41(1):131. doi: 10.1186/s13046-022-02294-5. J Exp Clin Cancer Res. 2022. PMID: 35392965 Free PMC article.
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Griffiths J, Hussain K, Smith HL, Sanders T, Cox KL, Semmrich M, Mårtensson L, Kim J, Inzhelevskaya T, Penfold CA, Tutt AL, Mockridge CI, Chan HC, English V, French RF, Teige I, Al-Shamkhani A, Glennie MJ, Frendeus BL, Willoughby JE, Cragg MS. Griffiths J, et al. Among authors: glennie mj. J Immunother Cancer. 2020 Dec;8(2):e001557. doi: 10.1136/jitc-2020-001557. J Immunother Cancer. 2020. PMID: 33428585 Free PMC article.
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Yeboah M, Papagregoriou C, Jones DC, Chan HTC, Hu G, McPartlan JS, Schiött T, Mattson U, Mockridge CI, Tornberg UC, Hambe B, Ljungars A, Mattsson M, Tews I, Glennie MJ, Thirdborough SM, Trowsdale J, Frendeus B, Chen J, Cragg MS, Roghanian A. Yeboah M, et al. Among authors: glennie mj. JCI Insight. 2020 Sep 1;5(18):e141593. doi: 10.1172/jci.insight.141593. JCI Insight. 2020. PMID: 32870822 Free PMC article.
186 results